2024-05-04 12:33:09 ET
Ascendis Pharma A/S (ASND)
Q1 2024 Earnings Conference Call
May 02, 2024, 04:30 PM ET
Company Participants
Tim Lee - Senior Director, Investor Relations
Jan Mikkelsen - President & Chief Executive Officer
Scott Smith - Executive Vice President & Chief Financial Officer
Stina Singel - Executive Vice President, Clinical Development, Oncology
Joe Kelly - US General Manager
Conference Call Participants
Jessica Fye - JPMorgan
David Lebowitz - Citi
Li Watsek - Cantor
Joseph Schwartz - Leerink Partners
Gavin Clark-Gartner - Evercore ISI
Kelly Shi - Jefferies
Derek Archila - Wells Fargo
Paul Choi - Goldman Sachs
Vikram Purohit - Morgan Stanley
Leland Gershell - Oppenheimer
Sushila Hernandez - Kempen
Presentation
Operator
Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there'll be a question-and-answer session. [Operator Instructions] As a reminder, this call may be recorded.
I would now like to turn the call over to Tim Lee, Senior Director, Investor Relations, Ascendis Pharma. Please go ahead.
Tim Lee
Thank you, operator, and thank you, everyone, for joining our first quarter 2024 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President of Clinical Development, Oncology; and Joe Kelly, US General Manager.
Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statement may include but are not limited to statements regarding our commercialization and continued development of SKYTROFA for the US and European markets, as well as certain financial expectations for 2024, our commercialization and development of YORVIPATH in the EU and expected timing of the FDA review and potential launch of TransCon PTH in the US, our pipeline candidates and our expectations with respect to their continued progress and potential commercialization, our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, our ongoing and planned regulatory filings, and our expectations regarding the timing and the results of regulatory decisions, our ability to create value in multiple therapeutic areas outside of endocrinology rare disease and our progress towards Vision 2030.
These statements are based on information that is available to us today. Actual results may differ -- could differ materially from those in our forward-looking statements, and you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change, except as required by law. For additional information concerning the factors that can cause actual results to differ materially, please see our forward-looking statements section in today's press release and the risk factors section of our most recent annual report on Form 20-F filed with the SEC on February 7, 2024....
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript